This is a proposal for the continued support of Indiana University's participation in Children's Cancer Group (CCG) activities. The Indiana University program has been a funded member of CCG since 1971. It serves as an important resource for study subjects as it ranks 4th in study entries (245) and 4th in total patients in active follow-up in CCG (1070) for the 12 month period ending 7/31/92. Study participation has been broad including therapeutic (first line, second line, new agents) as well as non-therapeutic studies (epidemiologic, biologic). Importantly, study participation has increase by 68% since 1989 at the Indiana University program. Members of the Indiana University program serve on 4 strategy groups (Wilm's, ANLL, Neuroblastoma, Brain Tumor) and serve as chairman of 2 other scientific committees in CCG (Local Tumor Control, Cytogenetics) demonstrating a significant contribution to the scientific activities. Participation and contributions to CCG activities by the Indiana University program will continue to grow. The Section of Pediatric Hematology/Oncology at Indiana University has added 8 new faculty members since July, 1991. Seven of 12 faculty have one or more NIH grants and one is a Howard Hughes Medical Institute Associate Investigator. Six of these new faculty have or will assume leadership roles in study and scientific committees in CCG. New areas of interest represented by these faculty include neuro-oncology, late effects of cancer therapy, acute non- lymphoblastic leukemia, neuroblastoma, germ cell tumors, cytokines and cancer biology. This compliments our current CCG activities in the areas of cytogenetics, tumor imaging, acute lymphoblastic leukemia, and Wilms' tumor. In regard to patient entry on study, it is anticipated that the Indiana University program will place up to 260 patients/year on CCG studies during the project period. Finally, Indiana University personnel are dedicated to protocol compliance and high quality data management in order to ensure the highest quality clinical science.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA013809-22
Application #
2086174
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1994-03-11
Project End
1998-11-30
Budget Start
1994-03-11
Budget End
1994-11-30
Support Year
22
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Indiana University-Purdue University at Indianapolis
Department
Pediatrics
Type
Schools of Medicine
DUNS #
005436803
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Seitzman, Robin L; Glover, Dorie A; Meadows, Anna T et al. (2004) Self-concept in adult survivors of childhood acute lymphoblastic leukemia: a cooperative Children's Cancer Group and National Institutes of Health study. Pediatr Blood Cancer 42:230-40
Shamberger, Robert C; LaQuaglia, Michael P; Gebhardt, Mark C et al. (2003) Ewing sarcoma/primitive neuroectodermal tumor of the chest wall: impact of initial versus delayed resection on tumor margins, survival, and use of radiation therapy. Ann Surg 238:563-7; discussion 567-8
Davies, Stella M; Bhatia, Smita; Ross, Julie A et al. (2002) Glutathione S-transferase genotypes, genetic susceptibility, and outcome of therapy in childhood acute lymphoblastic leukemia. Blood 100:67-71
Lange, Beverly J; Bostrom, Bruce C; Cherlow, Joel M et al. (2002) Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 99:825-33
Ou, Shu Xiao; Han, Dehui; Severson, Richard K et al. (2002) Birth characteristics, maternal reproductive history, hormone use during pregnancy, and risk of childhood acute lymphocytic leukemia by immunophenotype (United States). Cancer Causes Control 13:15-25
Cairo, M S; Krailo, M D; Morse, M et al. (2002) Long-term follow-up of short intensive multiagent chemotherapy without high-dose methotrexate ('Orange') in children with advanced non-lymphoblastic non-Hodgkin's lymphoma: a children's cancer group report. Leukemia 16:594-600
Wells, R J; Arthur, D C; Srivastava, A et al. (2002) Prognostic variables in newly diagnosed children and adolescents with acute myeloid leukemia: Children's Cancer Group Study 213. Leukemia 16:601-7
Cooper, R; Khakoo, Y; Matthay, K K et al. (2001) Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: histopathologic features-a report from the Children's Cancer Group. Med Pediatr Oncol 36:623-9
Heifetz, S A; Cushing, B; Giller, R et al. (1998) Immature teratomas in children: pathologic considerations: a report from the combined Pediatric Oncology Group/Children's Cancer Group. Am J Surg Pathol 22:1115-24
Heerema, N A; Palmer, C G; Baehner, R L (1985) Karyotypic and clinical findings in a consecutive series of children with acute lymphocytic leukemia. Cancer Genet Cytogenet 17:165-79